-
Innovation Ranking
NewInnovation Ranking – Affimed NV
Affimed NV (Affimed), is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. It develops pipeline products for the treatment of cancers. The pipleline products includes AFM13, AFM24, AFM28. AFM13 is a first of its kind ICE that is intended to treat certain CD30-positive (CD30+) cancers, such as Hodgkin lymphoma and other types of lymphomas. AFM24 is an epidermal growth factor receptor. AFM24 was developed to address limitations of current therapeutic anti-EGFR monoclonal antibodies, such as treatment resistance...
-
Product Insights
NewNet Present Value Model: Affimed NV’s AFM-24I
Empower your strategies with our Net Present Value Model: Affimed NV's AFM-24I report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Affimed NV’s AFM-13
Empower your strategies with our Net Present Value Model: Affimed NV's AFM-13 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Metastatic Pancreatic Cancer Drug Details: AVA-6000 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Malignant Fibrous Histiocytoma Drug Details: AVA-6000 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Solid Tumor Drug Details: AVA-6000 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Esophageal Cancer Drug Details: AVA-6000 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Pancreatic Ductal Adenocarcinoma Drug Details: AVA-6000 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Metastatic Biliary Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Metastatic Biliary Tract Cancer Drug Details: AVA-6000...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AVA-6000 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVA-6000 in Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVA-6000 in Breast Cancer Drug Details: AVA-6000 is under development for...